News
Public · Published
Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting
Cullinan Therapeutics announced that CLN-049, a FLT3xCD3 T cell engager, and velinotamig, a BCMAxCD3 T cell engager, will be featured in four posters at the 68th American Society of Hematology meeting, scheduled for December 12–15 in New Orleans. The company plans updated CLN-049 dose-escalation data and posters on both programs.
Published:
Updated:
What happened
Cullinan Therapeutics announced that CLN-049, a FLT3xCD3 T cell engager, and velinotamig, a BCMAxCD3 T cell engager, will be featured in four posters at the 68th American Society of Hematology meeting, scheduled for December 12–15 in New Orleans. The company plans updated CLN-049 dose-escalation data and posters on both programs.
Confirmed
Global impact / market context
The presentations may give investors more information about whether these experimental treatments show activity and manageable safety, especially for CLN-049 in blood cancers. Stronger evidence could support further clinical development, while the announced presentations alone do not establish that either treatment works or will reach patients.
Analyst inference
The article describes a clinical-stage drug company, so its programs remain in testing rather than being established products. The planned posters cover early-stage clinical data and studies still in progress; they may inform development decisions, but the article gives no approval, sales, spending, or financing update.
Analyst inference
What to watch
- At the meeting, check the CLN-049 poster for updated results at the selected 6 and 12 µg/kg Phase 2 target doses, including activity and safety details. Confirmed
- Look for the planned CLN-049 combination study with azacitidine and venetoclax in newly diagnosed AML, which may clarify the next clinical development path. Confirmed
- Review the velinotamig posters for details on its ongoing studies and preclinical findings; stronger evidence could support broader testing, but would not establish clinical benefit. Analyst inference